Innate Pharma is laying off 30% of its workforce while putting its efforts and resources behind three of the company’s pipeline assets with the “highest potential” of delivering value both to patients and the biotech’s shareholders.
All entries for: Immune Diseases
September 12, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck will terminate research and discovery efforts in the U.K., a move that includes pulling out of the Francis Crick Institute and the London BioScience Innovation Center, which will leave 125 employees jobless. The pharma giant is also pulling the plug on a roughly $1.3 billion construction project that was expected to open 120 posts for researchers and technicians. A company spokesperson said the moves reflect “the challenges of the U.K. not making meaningful progress towards addressing the lack of investment in the life science industry.” Successive U.K. governments, the spokesperson continued, have also demonstrated an “overall undervaluation of innovative medicines and vaccines.”
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 21, 2025
CSL
Layoffs
King of Prussia, PA
10,001-50,000 employees
Australian multinational CSL is parting ways with 15% of its workforce as part of a sweeping restructuring push, with an eye toward streamlining its operations and boosting its clinical and commercial performance.
As part of this strategic initiative, CSL will also spin off its vaccines business, CSL Seqirus, into its own independent entity, effective before its 2026 financial year ends in June next year. The pharma will also cut back on its overall expenditure, “including consolidation of R&D footprint.”
Disease Area: Hematology, Immune Diseases, Neurological Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
August 15, 2025
Vedanta Biosciences
Layoffs
Cambridge, MA
51-200 employees
Bausch Health has laid off 49 employees in Petaluma, California, and is closing that location. The cuts, effective Aug. 13, represent a small part of the Canada-based company’s workforce. Bausch employed about 20,700 employees—including 8,100 in the U.S. and Canada—as of Dec. 31
Disease Area: Gastrointestinal, Immune Diseases, Multiple
Drug Type: Biologic
August 13, 2025
Fate Therapeutics
Layoffs
San Diego, CA
51-200 employees
Some 12% of employees at Fate Therapeutics are on the chopping block as the California-based biotech seeks to extend its cash runway through the end of 2027. Fate had 181 full-time employees as of Dec. 31, indicating that this latest round of cuts could affect some 22 people.
Disease Area: Chronic Disease, Immune Diseases, Oncology
Drug Type: Biologic
August 12, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck will let go of 58 people at its Rahway, New Jersey, headquarters effective Nov. 14. The layoffs come after Merck confirmed it will execute $3 billion in cost cuts to support the launches of more than 20 products nearing the market. The move could affect roughly 6,000 employees during the multi-year move. Merck is paring back its workforce to help support the launches of 20 products nearing the market, according to a July 29 announcement. The cuts include eliminating administrative, sales and research and development roles.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Cambridge, MA
1,001-5,000 employees
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule